Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in ...

L’Oréal just announced it acquired a 10% stake in Galderma, characterized as a “pure play dermatology leader” in injectibles with Botox-competitor Dysport, and Restylane filler brands.

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. The US regulator cleared the IL-31 ...